Awareness and Attitude Relating to the Human Papilloma Virus and its Vaccines Among Pediatrics, Obstetrics and Gynecology Specialists in Turkey

  • Tolunay, Orkun (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Celik, Umit (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Karaman, Seyfettin Senih (Department of Obstetrics and Gynecology, Adana Numune Training and Research Hospital) ;
  • Celik, Tamer (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Resitoglu, Salim (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Donmezer, Cigdem (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Aydin, Fahri (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Baspinar, Huseyin (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Mert, Mustafa Kurthan (Department of Pediatrics, Adana Numune Training and Research Hospital) ;
  • Samsa, Hasan (Department of Pediatrics, Kayseri Training and Research Hospital) ;
  • Arli, Sefa (Department of Pediatrics, Kayseri Training and Research Hospital)
  • Published : 2015.01.22


Background: To determine the level of knowledge on human papillomavirus (HPV) infection and vaccination, and the attitude towards HPV vaccination in pediatricians, obstetricians and gynecologists (OBG). Materials and Methods: Participants were administered a 40-question survey, investigating the demographic properties, the knowledge on the HPV infection-vaccination and attitudes towards vaccination. Results: The study enrolled a total of 228 participants (131 pediatricians and 97 OBGs). At a rate of 99.6%, the participants agreed with the fact that the HPV infection was the most common sexually transmitted disease and 33.8% of the participants had the opinion that the HPV vaccination should be administered only in women. The lowest level of HPV vaccine recommendation was among the pediatrics specialists (59.4%, p=0.012). When asked whether they would have their daughters receive HPV vaccination, 79.5% of the participants answered favorably; this rate was 36.7% for the sons. At a rate of 59.5% of the participants thought that the HPV vaccine needed to be included in the national vaccine schedule. Most of the participants (91.6%) had the idea that reduction of the vaccine costs would increase the vaccination frequency. Conclusions: We observed that the consideration of the costs and the prejudices relating to the inefficacy of vaccination as well as the inadequate level of knowledge were involved in the physicians' resistance to HPV vaccination. We believe that the healthcare professionals should be informed adequately to overcome false beliefs, thereby ensuring success of the HPV vaccine upon inclusion in the national vaccine schedule in the future.


  1. Akcali S, Goker A, Ecemis T, Kandiloglu AR, Sanlidag T (2013). Human papilloma virus frequency and genotype distribution in a Turkish population. Asian Pac J Cancer Prev, 14,503-6.
  2. Alsaad MA, Shamsuddin K, Fadzil F (2012). Knowledge towards HPV infection and HPV vaccines among Syrian Mothers. Asian Pac J Cancer Prev. 13, 879-83.
  3. Basara BB, Guler C, Yentur GK, et al (2013). The Ministry of Health of Turkey health statistics yearbook 2012. General Directorate of Health Research, Republic of Turkey Ministry of Health, 2013. Avaible at:
  4. Castellsague X, Cohet C, Puig-Tintore LM, et al (2008). Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health, 19, 106-10.
  5. Ceyhan M. Problems in HPV Vaccination in Turkey (2007). ANKEM Derg, 21, 102-104.
  6. Committee on Infectious Diseases (2012). HPV vaccine recommendations. Pediatrics, 129, 602-5.
  7. Daley MF, Liddon N, Crane LA, et al (2006). A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics, 118, 2280-9.
  8. Dursun P, Senger SS, Arslan H, et al (2009). Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit. BMC Infect Dis, 9, 191.
  9. Dursun P, Ayhan A, Mutlu L, et al (2013). HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers. Turk Patoloji Derg, 29, 210-6.
  10. El-All HS, Refaat A, Dandash K et al (2007). Prevalence of cervical neoplastic lesions and Human Papilloma Virus infection in Egypt: National Cervical Cancer Screening Project. Infect Agent Cancer, 2, 12.
  11. Frazer IH (2014). Development and implementation of papillomavirus prophylactic vaccines. J Immunol, 192, 4007-11.
  12. GM Clifford, JS Smith, T Aguado, et al (2003). Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer, 89, 101-5.
  13. Insinga RP, Dasbach EJ, Myers ER (2003). The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis, 36, 1397-403.
  14. Jaspers L, Budiningsih S, Wolterbeek R, et al (2011). Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia:A cross-sectional study. Vaccine, 29, 7785-93.
  15. Kahn JA, Zimet GD, Bernstein DI, et al (2005). Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health, 37, 502-10.
  16. Kim KS, Park SA, Ko KN, et al (2014). Current status of human papillomavirus vaccines. Clin Exp Vaccine Res, 3, 168-75.
  17. Koshiol JE, Laurent SA, Pimenta JM (2004). Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis, 31, 748-52.
  18. Mazza D, Petrovic K, Grech C, et al (2014). HPV vaccination in women aged 27 to 45 years: What do general practitioners think?. BMC Womens Health, 14, 91.
  19. Munoz N, Bosch FX, de Sanjose S, et al (2003). International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
  20. Nokiani FA, Akbari H, Rezaei M, et al (2008). Cost effectiveness of pap smear in Kermanshah, Iran. Asian Pac J Cancer Prev, 9, 107-10.
  21. Ortashi O, Raheel H, Shalal M, et al (2013). Awareness and knowledge about human papillomavirus infection and vaccination among women in UAE. Asian Pac J Cancer Prev, 14, 6077-80.
  22. Ozmen V, Boylu S, Ok E, et al (2014). Factors affecting breast cancer treatment delay in Turkey: a study from Turkish Federation ofBreast Diseases Societies. Eur J Public Health first published online August 5, 2014 doi:10.1093/eurpub/cku086
  23. Ozmen V, Nilufer Ozaydin A, Cabioglu N, et al (2011). Survey on a mammographic screening program in Istanbul, Turkey. Breast J, 17, 260-7.
  24. Ozsurekci Y, Karadag Oncel E, et al (2013). Knowledge and attitudes about human papillomaviruses and immunization among Turkish pediatricians. Asian Pac J Cancer Prev, 14, 7325-9.
  25. Ozcelik B, Serin IS, Gokahmetoglu S, et al (2013). Human papillomavirus frequency of women at low risk of developing cervical cancer: a preliminary study from a Turkish university hospital. Eur J Gynaecol Oncol, 24, 157-9.
  26. Riedesel JM, Rosenthal SL, Zimet GD, et al (2005). Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol, 18, 391-8.
  27. Sengul D, Altinay S, Oksuz H, et al (2014). Population-based cervical screening outcomes in Turkey over a period of approximately nine and a half years with emphasis on results for women aged 30-34. Asian Pac J Cancer Prev, 15, 2069-74.
  28. Trottier H, Franco EL (2006). The epidemiology of genital human papillomavirus infection. Vaccine, 24, 1-15.
  29. Varma S, Lathrop E, Haddad LB (2013). Pediatric condyloma acuminata. J Pediatr Adolesc Gynecol, 26, 121-2.
  30. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  31. Wong LP (2009). Preventing cervical cancer through human papillomavirus vaccination: perspective from focus groups. J Low Genit Tract Dis, 13, 85-93.
  32. World Health Organization (2006). Comprehensive cervical cancer control: a guide to essential practice.

Cited by

  1. Gynecologistsʼ Knowledge, Attitudes, and Intentions Toward Human Papillomavirus Vaccination in Serbia vol.21, pp.1, 2017,